Inducible nitric oxide synthase as a target for osteoarthritis treatment. (3rd April 2018)

• Record Type: Journal Article
• Authors: Leonidou, Andreas; Lepetsos, Panagiotis; Mintzas, Michalis; Kenanidis, Eustathios; Macheras, George; Tzetis, Maria; Potoupnis, Michael; Tsiridis, Eleftherios
• Is Part Of: Expert opinion on therapeutic targets. Volume 22:Number 4(2018:Apr.)
• Page Start: 299
• Page End: 318
• Publication Date: 2018-04-03
• Subjects: Inducible nitric oxide synthase -- nitric oxide -- IL-1 -- osteoarthritis; Drugs -- Research -- Periodicals; 615.072
• DOI: 10.1080/14728222.2018.1448062
• Languages: English
• ISSNs: 1744-7631

Abstract

ABSTRACT: Introduction : Inducible nitric oxide synthase (iNOS) is the enzyme responsible for the production of nitric oxide (NO), a major proinflammatory and destructive mediator in osteoarthritis (OA). Areas covered : This is a comprehensive review of the recent literature on the involvement of iNOS in osteoarthritis and its potential to be used as a target for OA treatment. Evidence from in vitro, in vivo and human studies was systematically collected using medical search engines. Preclinical studies have focused on the effect of direct and indirect iNOS inhibitors in both animal and human tissues. Apart from direct inhibitors, common pharmacological agents, herbal and dietary medicines as well as hyperbaric oxygen, low level laser and low intensity pulsed ultrasound have been shown to exhibit a chondroprotective effect by inhibiting the expression of iNOS. Expert opinion : Data support the further investigation of iNOS inhibitors for the treatment of OA in human studies and clinical trials. Indirect iNOS inhibitors such as interleukin 1 inhibitors also need to be studied in greater detail. Finally, human studies need to be conducted on the herbal and dietary medicines and on the non-invasive, non-pharmacological treatments.